Tandem Diabetes Care (TNDM) Receivables (2013 - 2026)

Tandem Diabetes Care has reported Receivables for 14 years, with the latest figure at $147.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 16.61% year-over-year to $147.6 million; the trailing twelve-month figure through Mar 2026 stood at $147.6 million (up 16.61% YoY), and the FY2025 full-year result was $165.5 million, up 44.43% from the prior year.
• Receivables for Q1 2026 stood at $147.6 million, down from $165.5 million in the prior quarter.
• The five-year high for Receivables was $165.5 million in Q4 2025, with the low at $91.4 million in Q1 2023.
• Historically, Receivables has averaged $114.0 million across 5 years, with a median of $107.2 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables decreased 11.33% — and 2025, when it jumped 44.43%.
• Tandem Diabetes Care's Receivables stood at $119.0 million in 2022, then decreased by 11.33% to $105.6 million in 2023, then rose by 8.55% to $114.6 million in 2024, then surged by 44.43% to $165.5 million in 2025, then fell by 10.82% to $147.6 million in 2026.
• The last three Receivables figures came in at $147.6 million (Q1 2026), $165.5 million (Q4 2025), and $125.9 million (Q3 2025), per Business Quant data.